[Clinicoimmunological monitoring of therapy in patients with associated forms of yersiniosis].

Abstract

Characteristics of the clinical process and immunological profile in children with yersiniosis as a monoinfection or in association with acute intenstinal infections and virus hepatitis A are presented. The efficacy of the immunotropic therapy with cycloferon, an interferon inductor, and recombinant interferon in the patients with the viral and bacterial association of the disease (yersiniosis + hepatitis A) and initial disbalance of the serum cytokines was estimated. Dependence of the interferon clinicolaboratory efficacy on the initial levels of serum y-interferon, IL2 and IIA, promoting shorter terms of hyperthermia, diarrhea syndrome and cytolysis syndrome was shown. It allowed to optimize the scheme of the pathogenetic therapy of Yersinia mixed infection.

• Authors: A V Gordeets, E N Iurusova, A N Smagina, S L Piskunova
• Journal: Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] (Antibiot Khimioter) Vol. 56 Issue 5-6 Pg. 49-53 ( 2011) ISSN: 0235-2990 [Print] Russia (Federation)
• PMID: 22145231 (Publication Type: Journal Article)

Chemical References

• Acridines
• Interferon Inducers
• Interferon alpha-2
• Interferon-alpha
• Interleukins
• Recombinant Proteins
• Interferon-gamma
• 10-carboxymethyl-9-acridanone

Topics

• Acridines (pharmacology, therapeutic use)
• Adolescent
• Case-Control Studies
• Child
• Child, Preschool
• Coinfection (etiology, therapy)
• Female
• Gastroenteritis (etiology, therapy)
• Hepatitis A (immunology, therapy)
• Humans
• Interferon Inducers (pharmacology, therapeutic use)
• Interferon alpha-2
• Interferon-alpha (pharmacology, therapeutic use)
• Interferon-gamma (analysis, metabolism)
• Interleukins (analysis, metabolism)
• Male
• Recombinant Proteins (pharmacology, therapeutic use)
• Yersinia pseudotuberculosis Infections (immunology, pathology, therapy)